Oligomerix this week added William Erhardt to its executive team as chief medical officer. Erhardt was most recently senior vice president, head of clinical development & operations at Pfizer (NYSE: [[ticker:PFE]]).
New York-based Oligomerix, which is headquartered at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine, is developing small molecule therapeutics designed to target tau oligomers in patients with Alzheimer’s disease and other neurodegenerative disorders. The biotech aims to start human tests next year.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
